MG
ESPR

Meditor Group’s Esperion Therapeutics ESPR Stock Holding History

Meditor Group’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$6.26M Hold
3,791,300
– – 12.99% 2
2024
Q2 		$8.42M Hold
3,791,300
– – 15.57% 2
2024
Q1 		$10.2M Hold
3,791,300
– – 14.93% 2
2023
Q4 		$11.3M Hold
3,791,300
– – 14.17% 2
2023
Q3 		$3.72M Sell
3,791,300
-611,673
-14% -$885K 4.82% 2
2023
Q2 		$6.12M Hold
4,402,973
– – 5.31% 2
2023
Q1 		$7M Sell
4,402,973
-65,862
-1% -$340K 5.58% 2
2022
Q4 		$27.8M Hold
4,468,835
– – 18.82% 2
2022
Q3 		$29.9M Hold
4,468,835
– – 19.92% 2
2022
Q2 		$28.4M Hold
4,468,835
– – 14.05% 2
2022
Q1 		$20.7M Hold
4,468,835
– – 8.65% 2
2021
Q4 		$22.3M Buy
4,468,835
+1,650,000
+59% +$13.2M 10.09% 2
2021
Q3 		$34M Hold
2,818,835
– – 11.67% 2
2021
Q2 		$59.6M Buy
2,818,835
+139,000
+5% +$3.35M 21.09% 2
2021
Q1 		$75.2M Hold
2,679,835
– – 21.12% 2
2020
Q4 		$69.7M Hold
2,679,835
– – 19.39% 2
2020
Q3 		$99.6M Hold
2,679,835
– – 22.32% 2
2020
Q2 		$138M Hold
2,679,835
– – 28.84% 2
2020
Q1 		$68.1M Hold
2,679,835
– – 23.47% 2
2019
Q4 		$121M Hold
2,679,835
– – 34.4% 2
2019
Q3 		$98.2M Hold
2,679,835
– – 23.93% 2
2019
Q2 		$125M Hold
2,679,835
– – 25.08% 2
2019
Q1 		$108M Hold
2,679,835
– – 20.17% 2
2018
Q4 		$123M Buy
2,679,835
+50,000
+2% +$2.41M 25.39% 2
2018
Q3 		$117M Hold
2,629,835
– – 25.08% 2
2018
Q2 		$103M Buy
2,629,835
+40,600
+2% +$2.05M 20.13% 2
2018
Q1 		$187M Buy
2,589,235
+266,400
+11% +$19.6M 29.46% 2
2017
Q4 		$153M Buy
2,322,835
+27,900
+1% +$1.5M 19.68% 2
2017
Q3 		$115M Buy
2,294,935
+1,728,935
+305% +$83.4M 17.46% 2
2017
Q2 		$26.2M Buy
+566,000
New +$20.8M 3.94% 3

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Meditor Group's ESPR Position: Q3 2024 in Review

Meditor Group held its Esperion Therapeutics (ESPR) position steady in Q3 2024 at 3,791,300 shares worth $6.26M. The position accounts for 12.99% of the portfolio, ranked #2.

Meditor Group first reported a position in ESPR in Q2 2017 and has held it in 30 quarters since. The position peaked at $187M in Q1 2018. 183 funds tracked by Wall St. Rank hold ESPR as of Q3 2024.

  • Meditor Group held 3,791,300 shares of Esperion Therapeutics worth $6.26M as of Q3 2024.
  • Meditor Group left its Esperion Therapeutics share count unchanged in Q3 2024.
  • Esperion Therapeutics made up 12.99% of Meditor Group's portfolio in Q3 2024, its #2 holding.
  • Meditor Group first reported a position in Esperion Therapeutics in Q2 2017 and has held it in 30 quarters since.
  • Meditor Group's Esperion Therapeutics position peaked at $187M in Q1 2018.
  • 183 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2024.

Based on Meditor Group's 13F filing for Q3 2024, filed 7 Oct 2024.